Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats
Table 1
Serum creatinine, calcium, and phosphate levels in study groups.
Age (weeks)
WT-C (n = 14)
WT-R (n = 13)
TG-C (n = 15)
TG-R (n = 14)
Serum creatinine (mg/dL)
5
0.25 ± 0.03
0.24 ± 0.02
0.26 ± 0.06
0.23 ± 0.04
8
0.36 ± 0.05
0.34 ± 0.06
0.33 ± 0.08
0.30 ± 0.06
12
0.47 ± 0.07
0.44 ± 0.03
0.42 ± 0.07
0.42 ± 0.06
Serum calcium (mg/dL)
5
10.23 ± 0.65
10.22 ± 0.52
9.69 ± 0.77
9.53 ± 0.62
8
10.66 ± 0.52
10.47 ± 0.36
10.31 ± 0.77
10.26 ± 0.54
12
10.79 ± 0.42
10.58 ± 0.67
10.85 ± 1.01
10.98 ± 0.93
Serum phosphate (mg/dL)
5
9.33 ± 0.95
9.66 ± 0.99
10.53 ± 2.23
9.03 ± 1.13
8
9.41 ± 1.57
8.78 ± 0.87
10.43 ± 2.97
9.50 ± 1.67
12
9.43 ± 1.74
9.05 ± 2.23
11.85 ± 5.12
12.14 ± 4.10
Rats were divided into experimental groups as follows: wild-type littermates (WT) without risedronate administration (WT-C), WT rats with risedronate administration (WT-R), type III Pi transporter-overexpressing transgenic (Pit-1 TG) rats with risedronate administration (TG-R), and Pit-1TG rats without risedronate administration (TG-C). Data are presented as mean ± SD. compared with WT-R group.
